NLRC5 and osteosarcoma: Taken together, these data support consideration of PRC2-directed clinical studies, particularly when single-cell maps indicate H3K27me3-dominated inaccessibility at NLRC5/HLA regulatory elements, while recognizing that osteosarcoma-specific trial data are still limited (94, 95).